Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants - Top-Institutions - MDSpire

Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants

  • By

  • Sarah H Berth

  • Linh Vo

  • Do Hoon Kwon

  • Tiffany Grider

  • Yasmine S Damayanti

  • Gage Kosmanopoulos

  • Andrew Fox

  • Alexander R Lau

  • Patrice Carr

  • Jack K Donohue

  • Maya Hoke

  • Simone Thomas

  • Chafic Karam

  • Alex J Fay

  • Ethan Meltzer

  • Thomas O Crawford

  • Rachelle Gaudet

  • Michael E Shy

  • Ute A Hellmich

  • Seok-Yong Lee

  • Charlotte J Sumner

  • Brett A McCray

  • July 18, 2024

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Genetics
    • Molecular Biology

  • #2

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Neurology
    • Genetics
    • Structural Biology

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Genetics
    • Cellular Physiology

  • #4

    National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS)
    National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS)

    Bethesda, MD

    Key Differentiators

    • Neurology
    • Genetics
    • Ion Channel Physiology

Original Source(s)

Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants

  • by Sarah H Berth, Linh Vo, Do Hoon Kwon, Tiffany Grider, Yasmine S Damayanti, Gage Kosmanopoulos, Andrew Fox, Alexander R Lau, Patrice Carr, Jack K Donohue, Maya Hoke, Simone Thomas, Chafic Karam, Alex J Fay, Ethan Meltzer, Thomas O Crawford, Rachelle Gaudet, Michael E Shy, Ute A Hellmich, Seok-Yong Lee, Charlotte J Sumner, Brett A McCray

  • July 18, 2024

Related Content

Ultrasound Models Estimate Whole-Body Muscle Mass

New equations incorporating cross-sectional area improve estimation accuracy.

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.